PURPOSE: The recombination factor Rad51 is highly expressed in human pancreatic adenocarcinoma. In this study we asked whether high-level expression of Rad51 antigen stimulates a B-cell response leading to Rad51-specific autoantibodies in human pancreatic cancer patients. METHODS: Sera of patients suffering from pancreatic cancer (57) as well as sera of healthy donors (86) were screened for Rad51 autoantibodies by Western-blot analysis. Rad51 over-expressing cell lines were used as antigen source. RESULTS: Four out of 57 (7%) sera tested were found positive for Rad51 autoantibodies of IgG subclass, while all 86 control sera were negative. CONCLUSION: This observation identifies Rad51 as a tumour-associated antigen in pancreatic adenocarcinoma. Since high-level expression of Rad51 is restricted to tumour cells, Rad51 is also a tumour-specific antigen. Further analyses should reveal whether Rad51 might also function as a tumour-specific transplantation antigen (TSTA) and whether it might serve as a target for new immunotherapeutical approaches.
PURPOSE: The recombination factor Rad51 is highly expressed in humanpancreatic adenocarcinoma. In this study we asked whether high-level expression of Rad51 antigen stimulates a B-cell response leading to Rad51-specific autoantibodies in humanpancreatic cancerpatients. METHODS: Sera of patients suffering from pancreatic cancer (57) as well as sera of healthy donors (86) were screened for Rad51 autoantibodies by Western-blot analysis. Rad51 over-expressing cell lines were used as antigen source. RESULTS: Four out of 57 (7%) sera tested were found positive for Rad51 autoantibodies of IgG subclass, while all 86 control sera were negative. CONCLUSION: This observation identifies Rad51 as a tumour-associated antigen in pancreatic adenocarcinoma. Since high-level expression of Rad51 is restricted to tumour cells, Rad51 is also a tumour-specific antigen. Further analyses should reveal whether Rad51 might also function as a tumour-specific transplantation antigen (TSTA) and whether it might serve as a target for new immunotherapeutical approaches.
Authors: Michelle C Silva; Milagros D Morrical; Katie E Bryan; April M Averill; Julie Dragon; Jeffrey P Bond; Scott W Morrical Journal: DNA Repair (Amst) Date: 2016-04-25
Authors: Michelle C Silva; Katie E Bryan; Milagros D Morrical; April M Averill; Julie Dragon; Adrian P Wiegmans; Scott W Morrical Journal: DNA Repair (Amst) Date: 2017-10-23
Authors: Jianhong Chen; Milagros D Morrical; Katherine A Donigan; Joanne B Weidhaas; Joann B Sweasy; April M Averill; Jennifer A Tomczak; Scott W Morrical Journal: Nucleic Acids Res Date: 2014-12-24 Impact factor: 16.971
Authors: Su-Hyung Hong; David E Misek; Hong Wang; Eric Puravs; Robert Hinderer; Thomas J Giordano; Joel K Greenson; Dean E Brenner; Diane M Simeone; Craig D Logsdon; Samir M Hanash Journal: Biomark Insights Date: 2006
Authors: Carolyn G Marsden; Ryan B Jensen; Jennifer Zagelbaum; Eli Rothenberg; Scott W Morrical; Susan S Wallace; Joann B Sweasy Journal: PLoS Genet Date: 2016-08-11 Impact factor: 5.917